Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration …
Background: Glioblastoma (GBM) is the most common brain tumor with an overall survival
(OS) of less than 30% at two years. Valproic acid (VPA) demonstrated survival benefits …
(OS) of less than 30% at two years. Valproic acid (VPA) demonstrated survival benefits …